摘要
目的:探讨齐拉西酮对首发精神分裂症患者的临床疗效及安全性。方法:60例精神分裂症患者随机分为两组,分别给予齐拉西酮与利培酮治疗8周,用阳性与阴性症状量表(PANSS)和治疗中出现的症状量表(TESS)评定疗效和不良反应。结果:齐拉西酮组与利培酮组疗效相仿(P>0.05),齐拉西酮组不良反应显著少于利培酮组(P<0.05)。结论:齐拉西酮是一种安全有效的抗精神病药。
Objective： To study the clinical efficacy and side effects of ziprasidone in the treatment of first-onset -schizophrenia. Method： Sixty schizophrenic inpatients were divided into ziprasidone group or fisperidone group randondy for 8 weeks. Positive and negative symptoms scale （PANSS） and treatment emergent symptom scale （TESS） were used to evaluate the efficacy and side effects respectively. Results：There were no significant differences in efficacy between two groups （P 〉 0.05）. Ziprasidone had less side effects than risperidone significantly （P 〈 0.05）. Conclusion：Ziprasidone is a safe and effective antipsychotic drug.
出处
《临床精神医学杂志》
2008年第1期55-56,共2页
Journal of Clinical Psychiatry
